A Personalized Cancer Vaccine that Induces Synergistic Innate and Adaptive Immune Responses

© 2023 Wiley-VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 35(2023), 36 vom: 30. Sept., Seite e2303080
1. Verfasser: Kuen, Da-Sol (VerfasserIn)
Weitere Verfasser: Hong, Jihye, Lee, Suyoung, Koh, Choong-Hyun, Kwak, Minkyeong, Kim, Byung-Seok, Jung, Mungyo, Kim, Yoon-Joo, Cho, Byung-Sik, Kim, Byung-Soo, Chung, Yeonseok
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article acute myeloid leukemia cytotoxic T cells extracellular nanovesicles iNKT cells memory immunity personalized vaccines Cancer Vaccines
LEADER 01000caa a22002652c 4500
001 NLM357511883
003 DE-627
005 20250304202424.0
007 cr uuu---uuuuu
008 231226s2023 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.202303080  |2 doi 
028 5 2 |a pubmed25n1191.xml 
035 |a (DE-627)NLM357511883 
035 |a (NLM)37249019 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Kuen, Da-Sol  |e verfasserin  |4 aut 
245 1 2 |a A Personalized Cancer Vaccine that Induces Synergistic Innate and Adaptive Immune Responses 
264 1 |c 2023 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 08.09.2023 
500 |a Date Revised 08.09.2023 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2023 Wiley-VCH GmbH. 
520 |a To demonstrate potent efficacy, a cancer vaccine needs to activate both innate and adaptive immune cells. Personalized cancer vaccine strategies often require the identification of patient-specific neoantigens; however, the clonal and mutational heterogeneity of cancer cells presents inherent challenges. Here, extracellular nanovesicles derived from alpha-galactosylceramide-conjugated autologous acute myeloid leukemia (AML) cells (ECNV-αGC) are presented as a personalized therapeutic vaccine that activates both innate and adaptive immune responses, bypassing the need to identify patient-specific neoantigens. ECNV-αGC vaccination directly engages with and activates both invariant natural killer T (iNKT) cells and leukemia-specific CD8+ T cells in mice with AML, thereby promoting long-term anti-leukemic immune memory. ECNV-αGC sufficiently serves as an antigen-presenting platform that can directly activate antigen-specific CD8+ T cells even in the absence of dendritic cells, thereby demonstrating a multifaceted cellular mechanism of immune activation. Moreover, ECNV-αGC vaccination results in a significantly lower AML burden and higher percentage of leukemia-free survivors among cytarabine-treated hosts with AML. Human AML-derived ECNV-αGCs activate iNKT cells in both healthy individuals and patients with AML regardless of responsiveness to conventional therapies. Together, autologous AML-derived ECNV-αGCs may be a promising personalized therapeutic vaccine that efficiently establishes AML-specific long-term immunity without requiring the identification of neoantigens 
650 4 |a Journal Article 
650 4 |a acute myeloid leukemia 
650 4 |a cytotoxic T cells 
650 4 |a extracellular nanovesicles 
650 4 |a iNKT cells 
650 4 |a memory immunity 
650 4 |a personalized vaccines 
650 7 |a Cancer Vaccines  |2 NLM 
700 1 |a Hong, Jihye  |e verfasserin  |4 aut 
700 1 |a Lee, Suyoung  |e verfasserin  |4 aut 
700 1 |a Koh, Choong-Hyun  |e verfasserin  |4 aut 
700 1 |a Kwak, Minkyeong  |e verfasserin  |4 aut 
700 1 |a Kim, Byung-Seok  |e verfasserin  |4 aut 
700 1 |a Jung, Mungyo  |e verfasserin  |4 aut 
700 1 |a Kim, Yoon-Joo  |e verfasserin  |4 aut 
700 1 |a Cho, Byung-Sik  |e verfasserin  |4 aut 
700 1 |a Kim, Byung-Soo  |e verfasserin  |4 aut 
700 1 |a Chung, Yeonseok  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 35(2023), 36 vom: 30. Sept., Seite e2303080  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnas 
773 1 8 |g volume:35  |g year:2023  |g number:36  |g day:30  |g month:09  |g pages:e2303080 
856 4 0 |u http://dx.doi.org/10.1002/adma.202303080  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 35  |j 2023  |e 36  |b 30  |c 09  |h e2303080